U.S. Labor Department requires PBMs to disclose fees in push to lower drug costs

U.S. Labor Department requires PBMs to disclose fees in push to lower drug costs
Labor targets PBM fees

A new federal transparency measure is targeting the opaque compensation practices that shape prescription drug costs for employer health plans. The rule requires pharmacy benefit managers to disclose hidden fees and compensation to employers, a change supporters say could help businesses negotiate better terms for workers and families.

Highlights

  • U.S. Department of Labor issued a final rule mandating pharmacy benefit managers disclose all fees and compensation to employer health plans.
  • House Committee on Education and the Workforce unanimously passed the PBM Kickback Prohibition Act (H.R. 7895) in May, targeting kickbacks to brokers and consultants.
  • Congressional scrutiny of PBM practices intensifies as lawmakers investigate hidden fees, kickbacks, and pricing structures impacting prescription drug costs for employees.

Rule expands pricing transparency for employer health plans

As reported by House Committee on Education and the Workforce, Committee Chair Tim Walberg is backing the Department of Labor's final rule requiring pharmacy benefit managers to disclose hidden fees and compensation to employers.

Walberg says PBMs have long relied on complex pricing arrangements that leave Americans paying higher costs, and he credits the Trump administration and Labor Secretary Sonderling with moving to give employers clearer information on prescription drug spending. He describes the rule as another step toward reducing drug costs for American families.

Congressional scrutiny of PBM practices continues

Lawmakers on the committee are already advancing related legislation aimed at PBM business practices. In May, the committee unanimously passed the PBM Kickback Prohibition Act, H.R. 7895, introduced by Health, Employment, Labor, and Pensions Subcommittee Chair Rick Allen.

The bill would bar PBMs from paying kickbacks to brokers and consultants in exchange for steering employers toward particular PBMs, an arrangement lawmakers say creates conflicts of interest and can raise prescription drug costs. The committee also held an April hearing examining how hidden fees, kickbacks and complex pricing structures affect workers and their families.

Our earlier coverage on sovereign resilience in a higher-rate environment explained how prolonged geopolitical tensions and elevated public spending are straining government finances and raising refinancing risks. We noted that persistent shocks—such as energy and food price spikes linked to ongoing conflicts—can keep inflation elevated and worsen debt-service burdens, especially in emerging and frontier markets with narrower revenue bases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.